Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.43 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 4/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | CES1 | P23141 | 1/20 | 0.39 |
| ▸ | CLK2 | P49760 | 1/20 | 0.38 |
| ▸ | CLK3 | P49761 | 1/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.37 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30734351 | 0.81 | MKNK1 (0.46) | MKNK1MKNK2CYP11B1CYP11B2CYP1A2 | |
| SCHEMBL8240390 | 0.81 | MKNK1 (0.46) | MKNK1MKNK2CYP11B1CYP11B2CYP1A2 | |
| SCHEMBL1915774 | 0.81 | KDM4E (0.46) | CYP1A2CYP2C19CES2CES1 | |
| SCHEMBL1857947 | 0.80 | HCAR2 (0.55) | CYP11B1CYP11B2CYP1A2CYP2C19CYP3A4 | |
| SCHEMBL7238664 | 0.80 | MKNK1 (0.49) | MKNK1MKNK2CYP11B1CYP11B2CYP1A2 | |
| SCHEMBL17518860 | 0.80 | GSK3B (0.56) | MKNK1MKNK2CYP11B1CYP11B2CYP1A2 | |
| SCHEMBL20963095 | 0.79 | CYP11B1 (0.40) | MKNK1MKNK2CYP11B1CYP11B2CYP1A2 | |
| SCHEMBL10475039 | 0.79 | MKNK1 (0.44) | MKNK1MKNK2CYP11B1CYP11B2CYP1A2 | |
| SCHEMBL17819556 | 0.79 | MKNK1 (0.44) | MKNK1MKNK2CYP11B1CYP11B2CYP1A2 | |
| Bromide SCHEMBL17503995 | 0.79 | GSK3B (0.54) | MKNK1MKNK2CYP11B1CYP11B2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2323988-A1 | ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR INHIBITORS | Wyeth LLC (US) | 2011-05-25 | — | — | EP | disclosed |
| US-20100130474-A1 | ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR INHIBITORS | WYETH (US) | 2010-05-27 | — | — | US | disclosed |
| WO-2010009290-A1 | ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR INHIBITORS | WYETH (US) | 2010-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130474-A1 | ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR INHIBITORS | CHRNA7, CHRNA6, CHRNA2 | MKNK1 1429/4885MKNK2 1101/4885CYP11B1 2089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.